Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 8
2022 13
2023 14
2024 11
2025 25
2026 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.
Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S. Yeang C, et al. J Am Coll Cardiol. 2022 Mar 22;79(11):1035-1046. doi: 10.1016/j.jacc.2021.12.032. J Am Coll Cardiol. 2022. PMID: 35300814 Free PMC article. Clinical Trial.
BACKGROUND: Laboratory methods that report low-density lipoprotein cholesterol (LDL-C) include both LDL-C and lipoprotein(a) cholesterol [Lp(a)-C] content. OBJECTIVES: The purpose of this study was to assess the effect of pelacarsen on directly measured Lp(a) …
BACKGROUND: Laboratory methods that report low-density lipoprotein cholesterol (LDL-C) include both LDL-C and lipoprotein(a) c …
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F, Giugliano RP. Duarte Lau F, et al. JAMA Cardiol. 2022 Jul 1;7(7):760-769. doi: 10.1001/jamacardio.2022.0987. JAMA Cardiol. 2022. PMID: 35583875 Review.
IMPORTANCE: Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). ...Nevertheless, emerging nucleic acid-based therapies, such as the antisense oligonucleotide pelacarsen and the small interfering RNA …
IMPORTANCE: Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). .. …
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a).
Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Cho L, et al. Am Heart J. 2025 Sep;287:1-9. doi: 10.1016/j.ahj.2025.03.019. Epub 2025 Apr 2. Am Heart J. 2025. PMID: 40185318 Free article.
BACKGROUND: Lipoprotein(a), abbreviated Lp(a), consists of apolipoprotein B-100 covalently bound to apolipoprotein(a), and represents an independent, genetically-determined, causal risk factor for atherosclerotic cardiovascular disease (CVD) and calcific aortic sten …
BACKGROUND: Lipoprotein(a), abbreviated Lp(a), consists of apolipoprotein B-100 covalently bound to apolipoprotein(a), and rep …
Lipoprotein(a) Lowering with Pelacarsen (TQJ230).
Sharma K, Kattamuri L, Mukherjee D. Sharma K, et al. Cardiovasc Hematol Disord Drug Targets. 2025 Oct 14. doi: 10.2174/011871529X399029250923100015. Online ahead of print. Cardiovasc Hematol Disord Drug Targets. 2025. PMID: 41102962
BACKGROUND: Elevated levels of lipoprotein(a) have been linked to an increased risk of Atherosclerotic Cardiovascular Disease (ASCVD). ...METHODOLOGY: We conducted a literature search on PubMed, Google Scholar, and Scopus using keywords such as "Pelacarsen", …
BACKGROUND: Elevated levels of lipoprotein(a) have been linked to an increased risk of Atherosclerotic Cardiovascular Disease …
Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease.
Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Fernandez-Prado R, et al. Clin Kidney J. 2020 Feb 11;13(5):753-757. doi: 10.1093/ckj/sfaa001. eCollection 2020 Oct. Clin Kidney J. 2020. PMID: 33123354 Free PMC article.
The reasons for the limited efficacy of statins in advanced CKD are unclear, but statins may increase plasma levels of the highly atherogenic molecule lipoprotein(a), also termed Lp(a), as well as PCSK9 (protein convertase subtilisin/kexin type 9) levels. ...Pela …
The reasons for the limited efficacy of statins in advanced CKD are unclear, but statins may increase plasma levels of the highly atherogeni …
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.
Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. Tasdighi E, et al. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28. Annu Rev Pharmacol Toxicol. 2024. PMID: 37506332 Free article. Review.
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). ...Evolving RNA-based therapeutics, such as the antisense …
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (L …
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent.
Hardy J, Niman S, Goldfaden RF, Ashchi M, Bisharat M, Huston J, Hartmann H, Choksi R. Hardy J, et al. Am J Cardiovasc Drugs. 2022 Jan;22(1):47-54. doi: 10.1007/s40256-021-00499-1. Epub 2021 Sep 7. Am J Cardiovasc Drugs. 2022. PMID: 34490591 Review.
Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. ...This review aims to present and discuss the current clinical and scientific evidenc …
Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, h …
Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS, Talasaz A, Mehta A, Kelly MS, Sisson EM, Bucheit JD, Brown R, Dixon DL. Alhomoud IS, et al. Pharmacotherapy. 2023 Oct;43(10):1051-1063. doi: 10.1002/phar.2851. Epub 2023 Jul 26. Pharmacotherapy. 2023. PMID: 37464942 Review.
Lipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. ...Three investigational compounds targeting Lp(a), including small interfering RNA (siRNA) agents (olpasiran, SLN36 …
Lipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apol …
Recent lipoprotein(a) trials.
Wei T, Cho L. Wei T, et al. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308. doi: 10.1097/MOL.0000000000000856. Curr Opin Lipidol. 2022. PMID: 36345866 Review.
PURPOSE OF REVIEW: Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and calcific aortic stenosis; thus, serum levels are minimally affected by conventional treatments for hypercholesterolemia and hypertriglyceride …
PURPOSE OF REVIEW: Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and c …
Pelacarsen: Mechanism of action and Lp(a)-lowering effect.
Bhatia HS, Bajaj A, Goonewardena SN, Moriarty PM. Bhatia HS, et al. J Clin Lipidol. 2025 Sep-Oct;19(5):1208-1222. doi: 10.1016/j.jacl.2025.06.004. Epub 2025 Jun 16. J Clin Lipidol. 2025. PMID: 40781022 Free article. Review.
BACKGROUND: Lipoprotein(a) (Lp[a]) is an apolipoprotein B100 (apoB)-containing lipoprotein with a single apolipoprotein(a) (apo[a]) covalently bound to apoB via a disulfide bond and oxidized phospholipids linked to apoB and apo(a), which is associated with proinflam …
BACKGROUND: Lipoprotein(a) (Lp[a]) is an apolipoprotein B100 (apoB)-containing lipoprotein with a single apolipoprotein(a) (ap …
77 results